A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | MicrobiomeTrials← Back to trialsNCT06406465
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-10-29Est. Completion: 2027-07-30
Enrollment target: 60 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Non-small Cell Lung Cancer (NSCLC)
All subjects will receive the vaccine subcutaneously every 3 weeks x 3 with optional yearly booster vaccines up to and i…
Pittsburgh, United StatesEst. completion Oct 2028
Extrapulmonary Neuroendocrine Carcinoma
This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 vers…
Multiple LocationsEst. completion Mar 26, 2029